/
Other
ART
94
Pipeline Programs↗
89
Active Trials↗
141
Companies Involved↗
ART is a moderately active landscape with 94 programs across 141 companies. The most active players are Eli Lilly, Terran Biosciences Australia Pty Ltd, Moderna. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical20
Phase 142
Phase 217
Phase 315
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
78 of 88 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 88 classified programs, each share of the total. Modality classified for 100% of 94 pipeline programs.
Analysis
Trial Status
1,017
clinical trials
Completed787 · 77%
Terminated71 · 7%
Recruiting44 · 4%
Unknown status43 · 4%
Not yet recruiting26 · 3%
Withdrawn23 · 2%
Other23 · 2%
Clinical Trials
Trial Activity
1017 trials
The Effect of Losartan on Cephalexin
Recruiting·—·Phase 1·NCT07300670·12 enrolled
Page 1 of 68
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)